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Abstract
Spinal muscular atrophy (SMA) is a progressive motor neuron disease caused by deleterious variants in SMN1 that lead
to a marked decrease in survival motor neuron (SMN) protein expression. Humans have a second SMN gene (SMN2) that
is almost identical to SMN1. However, due to alternative splicing the majority of SMN2 messenger ribonucleic acid (mRNA)
is translated into a truncated, unstable protein that is quickly degraded. Because the presence of SMN2 provides a unique
opportunity for therapy development in SMA patients, the mechanisms that regulate SMN2 splicing and mRNA expression
have been elucidated in great detail. In contrast, how much SMN protein is produced at different developmental time
points and in different tissues remains under-characterized. In this study, we addressed this issue by determining SMN
protein expression levels at three developmental time points across six different mouse tissues and in two distinct mouse
models of SMA (‘severe’ Taiwanese and ‘intermediate’ Smn2B/ mice). We found that, in healthy control mice, SMN protein
expression was significantly influenced by both age and tissue type. When comparing mouse models of SMA, we found
that, despite being transcribed from genetically different alleles, control SMN levels were relatively similar. In contrast,
the degree of SMN depletion between tissues in SMA varied substantially over time and between the two models. These
findings offer an explanation for the differential vulnerability of tissues and organs observed in SMA and further our
understanding of the systemic and temporal requirements for SMN with direct relevance for developing effective
therapies for SMA.
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Introduction
Spinal muscular atrophy (SMA) is a progressive motor neuron
disease (1). The most common form of SMA (50% of all cases;
type I) occurs in infants and is characterized by disease onset
before the age of 6 months and, when untreated, leads to death
before the age of 2 years. SMA is caused by the homozygous de-
letion of SMN1 (95%) or other mutations in SMN1 (5%) that
lead to a loss of survival motor neuron (SMN) protein expression
(2). Humans have a second SMN gene (SMN2) that is almost
identical to SMN1. However, due to a C-to-T transition at the 50
end of exon 7, exon 7 is removed by splicing from the majority
of SMN2 transcripts (3,4). The truncated SMN2 messenger ribo-
nucleic acid (mRNA) product is translated into an unstable pro-
tein that is quickly degraded (5). In contrast, a minority (10%)
of SMN2-derived mRNA includes exon 7, which is subsequently
translated into full-length, stable SMN protein. The number of
SMN2 copies in the human genome is variable, and therefore,
the number of SMN2 copies is the main determinant of the SMA
phenotype: a higher number of SMN2 copies correlates with
higher levels of full-length SMN which, in turn, correlates well
with the observed clinical phenotype (6). As such, the presence
of SMN2 provides a unique opportunity for therapy develop-
ment and the mechanisms that regulate SMN2 splicing have
been studied in great detail (7). Excitingly, this led to the recent
approval of nusinersen (Spinraza) for the treatment of SMA (8).
Nusinersen is an intrathecally delivered antisense oligonucleo-
tide that targets an intronic element upstream of exon 7,
leading to increased inclusion of exon 7 and increased levels of
full-length SMN protein. This is a milestone development that
leads to meaningful clinical improvement in a large group of
SMA patients (9,10).
In contrast, how SMN protein is expressed at different devel-
opmental time points and in different tissues is still poorly un-
derstood but remains important for several reasons. First,
although SMA is primarily a motor neuron disease, other cell
types and tissues are affected to varying degrees (11). The extent
to which this is related to varying SMN requirements between
tissues remains unknown; in general, RNA levels do not always
linearly correlate with protein levels and the amount of protein
translated from RNA varies between tissues (12). Second, a bet-
ter understanding of the relative SMN requirements in different
tissues will help guide the targeting of SMA therapy delivery: for
example, nusinersen is currently delivered directly to the cen-
tral nervous system (CNS) but this may not be sufficient to
achieve optimal therapeutic efficacy (13). Finally, recent re-
search has identified many cellular pathways that are affected
by SMN depletion in SMA (14,15). Although these findings con-
tribute to advancing our understanding of SMA pathogenesis,
they also illustrate the increasing need to identify common
pathways leading to pathology in SMA. Generating a reference
dataset of temporal and tissue-specific SMN expression levels
will help to interpret and prioritize the ongoing functional re-
search into the downstream cellular consequences of SMN
depletion.
Previous work has found that SMN protein levels are, as
expected, significantly reduced in tissue from SMA patients and
across disease models (Table 1). However, these studies are
challenging to compare directly, as: (1) different techniques
have been used to determine SMN levels, (2) when western blot
was used to determine SMN levels, varying loading controls
were used, (3) the number of studies that determine SMN levels
at different time points is limited and (4) often SMN expression
was determined in limited numbers of samples or replicates
that makes results difficult to interpret quantitatively. In this
study, we aimed to systematically address these issues by de-
termining SMN protein expression in six different tissues and at
three time points in both healthy control mice, and in two dis-
tinct mouse models of SMA. We used these results to first estab-
lish SMN protein levels in control mice and subsequently
quantify the relative decrease in SMN expression at each of the
time points in each of the investigated tissues for both models.
Our findings suggest that better understanding and appreciating
the significant variability in SMN expression in tissues, over
time and between models can provide a way to better under-
standing the differential vulnerability of tissues and cellular
pathways to SMN depletion.
Results
Quantification of protein levels across tissues and
throughout development
Accurate quantitative assessment of protein levels by western
blot requires a carefully controlled, reproducible and reliable
normalization method to account for differences in transfer effi-
ciency and gel loading. Traditionally, housekeeping proteins
such as actin, tubulin and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) have been used to normalize protein levels
for quantification purposes but these have several disadvan-
tages. First, the expression of housekeeping genes has been
shown to vary considerably between tissues, which makes it
difficult to select a single loading control for use across a range
of tissues (16). Moreover, housekeeping proteins show varying
expression levels during development, which complicates com-
parisons of protein levels obtained at different developmental
time points (17). Finally, many household proteins have been
shown to change in disease conditions. Indeed, several com-
monly used housekeeping proteins (actin, tubulin and GAPDH)
have been shown to be decreased in cellular models of SMA and
in tissues from SMA mouse models (16,18,19). To reliably nor-
malize protein levels, total protein stains (TPSs) (such as coo-
massie, ponceau S or fluorescently detectable variants) that
allow quantification of the total protein loaded are therefore
preferable (20). As in this study we aimed to quantify protein
levels across tissues and at different postnatal developmental
time points, we made use of a sensitive, quantitative western
blotting method based on laser-scanning detection of fluores-
cently labelled secondary antibodies and a fluorescent TPS. This
allowed us to normalize and quantify SMN levels across tissues
and throughout postnatal development (Fig. 1A). Fluorescent
TPSs and uncropped SMN western blots for all SMN blots in
each of the figures are included in Supplementary Material,
Figures S1–S5.
Variation in SMN expression between CNS and
peripheral tissues in control mice
First, we investigated SMN protein levels in control conditions
by using control littermates from the Taiwanese mouse model of
SMA (21). In this model, control and SMA-like mice are obtained
by breeding mice that are heterozygous for mouse Smn (Smnþ/)
with Smn-null mice that carry two alleles with two copies of
SMN2 (Smn/; SMN2tg/tg, total 4 copies SMN2) on a congenic FVB
background (22,23). Experimental litters subsequently consist of
50% control littermates (Smnþ/; SMN2tg/0, total one allele
mouse Smn and two copies of SMN2) and 50% severe SMA-like
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littermates (Smn/; SMN2tg/0, no mouse Smn and two copies of
SMN2). Control littermates develop completely normally (21).
Severe SMA-like littermates are initially not distinguishable from
controls. However, after several days a severe neuromuscular
and systemic phenotype develops, characterized by progressive
hind limb paralysis and extensive organ pathology (Fig. 1B, left
panel). The timing of the disease process varies slightly between
colonies, however, in our colony mice start developing symptoms
around postnatal day 4 (P4), which progressively worsen and lead
to an average survival of 8–9 days postnatally (P8/P9) (24). For this
study, we therefore defined pre-symptomatic as P2, early symp-
tomatic as P5 and late symptomatic as P8.
To establish between-tissue variability of SMN expression, we
determined SMN protein levels in three biological replicates from
control littermates (Smnþ/; SMN2tg/0) at the disease-relevant
time points P2, P5 and P8. We investigated SMN expression in six
different tissues: brain, spinal cord, muscle (M. gastrocnemius),
heart, liver and kidney (Fig. 2A and Supplementary Material, Fig.
S1). In addition to normalizing SMN levels to TPS, samples were
normalized to an internal standard to account for variability be-
tween membranes. The internal standard used in this and in
subsequent experiments consisted of a mixture of P5 brain
lysates (see Materials and Methods for further details) and
allowed us to quantify and directly compare SMN expression in
each of the investigated tissues (Fig. 2B). We found that the effect
of age on SMN expression significantly depended on the tissue
investigated and, vice versa, the effect of tissue on SMN expres-
sion significantly depended upon the age investigated (P< 0.001).
To examine this effect further, we performed post hoc analyses to
determine individual P-values for each of the time and tissue
comparisons (Supplementary Material, Table S1). At P2, SMN lev-
els were relatively similar in all of the tissues investigated, except
in liver where SMN levels were significantly lower. However, at
later time points substantially different patterns in SMN expres-
sion occurred. Brain and spinal cord SMN levels increased signifi-
cantly from P2 to P8. In contrast, SMN levels in muscle and
kidney decreased from P2 to P8 whereas heart SMN levels
remained constant. SMN expression in liver was significantly
lower at all times. These results indicate that SMN requirements
are likely different between nervous tissue and other types of tis-
sues over the normal process of postnatal development and mat-
uration in mice (Mus musculus).
A
B
Figure 1. Methods and mouse models used to determine SMN protein levels. (A) Overview of tissues collected from both mouse models used in this study. Tissues to
be analysed by quantitative western blotting included brain, spinal cord, skeletal muscle (M. gastrocnemius), heart, liver and kidney. (B) Taiwanese and Smn2B/ models of
SMA were used in this study. The Taiwanese model is based on a human transgene (SMN2), whereas the Smn2B/ model is based on a mutant mouse Smn allele.
Phenotypically, both models reflect core features of SMA, however, the Taiwanese shows a more pronounced systemic phenotype whereas the Smn2B/ model shows a
clearer neuromuscular phenotype (32).
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Figure 2. Analysis of SMN expression in control and Taiwanese SMA mice. (A) SMN expression in control littermates (Smnþ/; SMN2tg/0) of the Taiwanese model of SMA was
determined using western blot in the indicated tissues. Shown are the internal standard (Int. St.) that was the same for all tissues and loaded in triplicate on each membrane,
and SMN expression for each of the tissues at each of the indicated time points (P2, P5 and P8). (B) Quantification of SMN expression in all tissues from (A). Expression was first
normalized to a fluorescent TPS and then to the Int. St., to allow direct comparison between membranes (n ¼ 3 biological replicates for each of the tissues at each of the indi-
cated time points,6 SEM). All tissues for each time point were obtained from the same litter. (C) SMN expression is shown for each of the indicated tissues at pre-, early and
late-symptomatic ages (P2, P5 and P8) for both control (n ¼ 3 for each tissue and each time point, Smnþ/; SMN2tg/0) and SMA (n ¼ 3 for each tissue and each time point,
Smn/; SMN2tg/0) mice. (D) Quantification of relative SMN depletion in each of the tissues at each of the time points. SMN expression in each sample was first normalized to
a fluorescent TPS. SMN expression in SMA littermates is shown relative to control. (E) SMN levels were determined in each of the six tissues in two independent litters at the
late-symptomatic time point (P8). kDa: 40 kDa molecular weight marker, see Supplementary Material for uncropped western blot membranes.
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SMN depletion varies between tissues but is consistent
across litters in Taiwanese SMA mice
After observing a surprisingly large variability in SMN expres-
sion across tissues in control mice, we wanted to establish
whether similar variation was present in SMA mice. To assess
this, we determined the amount of SMN in SMA mice relative to
control littermates in each of the investigated tissues at P2, P5
and P8 (Fig. 2C and Supplementary Material, Fig. S2). SMN levels
were quantified in three SMA mice and three controls by first
normalizing expression to fluorescent TPS and then normaliz-
ing SMN levels in SMA to the average of three control litter-
mates (Fig. 2D, for percentages see Fig. 4C). Again, we observed
that the effect of age on SMN expression significantly depended
on the tissue investigated and that the effect of tissue on SMN
expression significantly depended on the age investigated
(P< 0.001). Post hoc analyses were performed to determine indi-
vidual P-values for each of the time and tissue comparison we
made (Supplementary Material, Table S2). In heart, muscle and
kidney, relative SMN expression was <5–10% of control SMN
levels, decreasing further over time. In liver, relative SMN ex-
pression in SMA was significantly higher than in heart, muscle
and kidney. In brain and spinal cord, significantly higher rela-
tive levels of SMN were present in SMA mice at P2 that de-
creased significantly over time to P8. This was in contrast to
SMN levels in control animals, where SMN levels initially in-
creased. This implies a particularly high requirement for SMN
in nervous tissues and, therefore, a relatively larger effect of
SMN depletion on nervous tissues than that on other tissues.
Finally, we were interested to see how reproducible SMN lev-
els were between separate litters of mice. Therefore, we deter-
mined SMN expression levels at P8 in a second, independent
litter (Fig. 2E) and compared SMN levels to those obtained before
(Fig. 2D). Although we observed some modest inter-litter vari-
ability, SMN levels between the two litters were comparable and
not significantly different in each of the tissues investigated.
This confirms that SMN depletion in SMA-like mice is reproduc-
ible between litters of the same mouse model.
SMN protein expression across tissues in the Smn2B/model
of SMA
The Taiwanese model of SMA is considered a model of severe
disease and is characterized by rapid progression leading to
death around P9. Requirement for SMN expression, however, is
thought to change substantially in the postnatal period up to
P20 (25). We therefore wanted to also study SMN protein levels
in an intermediate mouse model of SMA: Smn2B/ mice (Fig. 1B,
right panel). This model is based on a three-base pair substitu-
tion in the exon splicing enhancer region of exon 7 of mouse
Smn (reffered to as the Smn2B allele), that leads to SMN2-like
splicing of the mRNA (26,27). As for SMN2, the majority of its
protein product is truncated and rapidly degraded (28). Smn2B/
mice are generated by breeding mice that are homozygous for
the Smn2B allele (Smn2B/2B) with heterozygous Smnþ/ mice. This
leads to experimental litters that consist of 50% Smn2B/þ con-
trols and 50% Smn2B/ SMA-like mice. At birth, Smn2B/ mice
are indistinguishable from littermates, with symptom develop-
ment starting around P10. After this point, Smn2B/ mice fail to
gain weight in the same way as their control littermates.
Starting around P15, Smn2B/ mice show extensive pathology at
the neuromuscular junction, characterized by denervation, pre-
synaptic swelling and poor endplate maturation (29,30). The av-
erage survival of Smn2B/ mice varies depending on the genetic
background (31). Therefore, for the current experiments, we de-
fined P5 as pre-symptomatic, P10 as early symptomatic and P15
as late symptomatic.
First, as the time course of the Smn2B/ model is considerably
different than that of the Taiwanese model, we repeated the ex-
periment in which we determined SMN levels in control litter-
mates (Smn2B/þ, one copy of mouse Smn and one copy of the
Smn2B allele) at the disease-relevant time points of P5, P10 and
P15. As in the analysis for the Taiwanese model, we used brain,
spinal cord, muscle (M. gastrocnemius), heart, liver and kidney in
which we determined SMN protein levels by normalizing to
fluorescent TPS and subsequently normalized SMN expression
between membranes using an internal protein standard
that was analysed in triplicate and three biological replicates
for each tissue and each time point (Fig. 3A and B and
Supplementary Material, Fig. S3). In the Smn2B/ model of SMA,
we found that the effect of age on SMN expression significantly
depended upon the tissue investigated and, vice versa, the ef-
fect of tissue on SMN expression significantly depended upon
the age investigated (P< 0.001, Supplementary Material, Table
S1). In all tissues except liver SMN levels decreased significantly
from P5 to P15, however, SMN levels remained significantly
higher in brain and spinal cord than in other tissues at all time
points. In other tissues SMN decreased between P5 and P10 and
remained more constant from P10 to P15. Liver SMN expression
was significantly lower than all other tissues at P5 and
remained relatively constant over time.
After determining control SMN levels, we went on to inves-
tigate the extent of SMN depletion at each of the time points in
all six tissues of SMA littermates (Fig. 3C and Supplementary
Material, Fig. S4). Overall, the relative decrease in SMN expres-
sion was similar in all tissues (Fig. 3D and Supplementary
Material, Table S2). Relative SMN levels were all 20% of con-
trol levels at P5 and then decreased significantly over time to
10% of control at P15 (for percentages, see also Fig. 4C).
Interestingly, however, we did not observe significant differen-
ces between tissues at each of the time points. These results
indicate that, in the Smn2B/ model of SMA, similar variability
of SMN expression occurs between tissues in control mice but
that SMN depletion in SMA mice is more comparable between
tissues than in the Taiwanese model. Interestingly, systemic
pathology in the Taiwanese model is more pronounced than in
the Smn2B/ model (32) and these findings support the idea that
this variability is, at least in part, due to variability in SMN
expression.
Similarities and differences between Taiwanese and
Smn2B/models of SMA
We next wanted to investigate possible similarities and differ-
ences in SMN expression between the two models in more de-
tail. First, we needed to directly compare SMN expression in the
two mouse models by determining SMN levels in brain, kidney
and liver in P5 tissue from both models in a single experiment.
As before, SMN levels were normalized to TPS and subsequently
to an internal standard to account for variability between mem-
branes (Fig. 4A and B and Supplementary Material, Fig. S5). We
found that at P5, although protein levels in liver were signifi-
cantly lower (P¼ 0.013) in Smn2B/ compared with Taiwanese
mice, SMN levels in both mouse models were highly compara-
ble in each of the tissues investigated.
This finding allowed us to make several observations con-
cerning differences and similarities in SMN protein levels in the
Taiwanese and Smn2B/ models. First, in control tissues derived
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from both models, SMN levels in brain and spinal cord were sig-
nificantly higher than in other tissues. Moreover, SMN expres-
sion in kidney was high when compared with other peripheral
tissues. Although in the time course relevant to the Taiwanese
model (P2–P8) SMN expression still increased in control animals,
the analysis of the Smn2B/ time course illustrated that around
P10, SMN requirements started to decrease and at P15 SMN lev-
els in all tissues were lower than at P5. Surprisingly, when in-
vestigating SMN levels in SMA littermates, relative SMN
depletion varied significantly between tissues in Taiwanese mice
but was proportionally decreased in Smn2B/ mice (Fig. 4C).
Moreover, when investigating the changes in SMN expression
over time in more detail (Fig. 4D and E), we noticed that in
Taiwanese mice, spinal cord and brain relative SMN expression
was comparable at P2 and P5 but then declined sharply between
P5 and P8, consistent with disease onset and progression in this
model. In Smn2B/ mice, in contrast, SMN levels were compara-
ble across tissues, matching a more modest disease course as
observed in this model. The supplementary figures and tables
included with this article are provided to allow researchers to
make further comparisons between tissues and time points.
Because depletion of SMN is central to all pathways and pathol-
ogies observed in SMA, these results can provide a starting point
for further studies that will help to answer fundamental ques-
tions that remain in SMA research.
Discussion
We here present a comprehensive overview of SMN protein
expression variation across different tissues and at different
developmental time points in healthy control mice, as well as
in two established mouse models of SMA. As SMN levels were
determined using robust methodology we were able to make di-
rect and reliable comparisons between a severe and an interme-
diate SMA model. We found that, in control tissues, SMN levels
varied considerably across tissues and time points but were
A B
C D
Figure 3. Analysis of SMN expression in control mice and Smn2B/ SMA mice. (A) SMN expression in control littermates (Smnþ/; Smn2B/) of the Smn2B/ model of SMA
was determined using western blot in the indicated tissues. Shown are the Int. St. that was the same for all tissues and loaded in triplicate on each membrane, and
SMN expression for each of the tissues at each of the indicated time points (P5, P10 and P15). (B) Quantification of SMN expression in all tissues from (A). Expression
was first normalized to a fluorescent TPS and then to the Int. St., to allow direct comparison between membranes (n ¼ 3 biological replicates for each of the tissues at
each of the indicated time points, 6 SEM). (C) SMN expression is shown for each of the indicated tissues at pre-, early and late-symptomatic ages (P5, P10 and P15) for
both control (Smnþ/; Smn2B/) and SMA (Smn/; Smn2B/) mice. (D) Quantification of relative SMN depletion in each of the tissues at each of the time points. SMN ex-
pression in each sample was first normalized to a fluorescent TPS. SMN expression in SMA littermates is shown relative to control. kDa: 40 kDa molecular weight
marker, see Supplementary Material for uncropped western blot membranes.
2857|Human Molecular Genetics, 2018, Vol. 27, No. 16
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/16/2851/5001458 by Erasm
us U
niversity R
otterdam
 user on 29 O
ctober 2018
A B
C D
E
Figure 4. Comparison of SMN levels between the Taiwanese and Smn2B/ models of SMA. (A) SMN expression was determined by western blot in the indicated tissues
at P5 in both mouse models. Shown are the Int. St. that was the same for each tissue and loaded in triplicate on each membrane, and SMN expression in triplicate for
each tissue. kDa: 40 kDa molecular weight marker. (B) Quantification of SMN expression from the blots in (A), *P < 0.05 (t-test). Expression was first normalized to a fluo-
rescent TPS and then to the Int. St., to allow direct comparison between membranes. (C) Average of remaining SMN levels (6 SD) in both mouse models at each of the
investigated time points and tissues. (D) Relative depletion in SMN expression over time in Taiwanese mice. To allow easier comparison between tissues, P2 was set as
0 and expression values at P5 and P8 are shown relative to P2. (E) Relative depletion in SMN expression over time in Smn2B/ mice. To allow easier comparison between
tissues, P5 was set as 0 and expression values at P10 and P15 are shown relative to P5.
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comparable between the two mouse models. However, relative
SMN levels in SMA littermates from the same models were sub-
stantially different. Moreover, SMN expression levels were
found to be consistently higher in CNS tissues, indicating a
higher requirement for SMN in neural tissues compared with
non-neuronal tissues, comparable with the disease phenotypes
observed in SMA patients and mouse models.
SMN protein levels have been reported in several previous
studies (summarized in Table 1). Initial studies that used west-
ern blot to determine SMN levels in SMA patients often used a
variety loading controls and small sample numbers, and the
large variation in SMN levels thus obtained is therefore difficult
to interpret (28,31,33–36). The number of studies attempting to
determine SMN levels over time and in a number of tissues is
very limited and again, the use of different techniques [western
blot, SMN-electrochemiluminescence (SMN-ECL) and enzyme-
linked immunosorbent assay (ELISA)] makes it hard to compare
them directly (37–39). Moreover, several studies have focused
on determining SMN levels in peripherally accessible tissues
and patient cell lines such as blood, fibroblasts and induced-
pluripotent stem cell (iPSC)-derived motor neurons, including
investigating techniques that allow determining SMN levels in
relatively large groups of patients (37,38,40–44). These studies
have a primary use for drug and biomarker research and SMN
levels in whole blood or blood-derived cells such as lympho-
blasts and peripheral blood mononuclear cells (PBMCs) vary
quite extensively, seeming to depend partly on the techniques
used to determine SMN levels. Our current work overcomes the
issues that are present in previous studies by performing stan-
dardized western blot quantification methods across tissues,
time points and mouse models and thereby allows us to draw
more robust conclusions about the expression of SMN protein
during normal mouse development and the decrease in SMN
protein in SMA littermates. This is an important advance in our
understanding of the temporal and tissue requirements of SMN.
Intriguingly, we found that SMN expression in control mice
was similar in both models whereas, in contrast, the levels of
SMN that remained in SMA littermates were considerably differ-
ent. It is interesting to speculate what underlies this phenome-
non. In a previous study, wild-type mice (with two alleles of
mouse Smn) were compared with mice that were hemizygous
for Smn and SMA littermates (37). Here, the authors observed a
significant decrease in SMN in SMA littermates but only a small
difference between Smnþ/þand Smnþ/ mice. This implies that
under control conditions, SMN protein derived from one, wild-
type Smn allele is sufficient for most cell types and therefore the
presence of two copies of SMN2 (Taiwanese model) or a mouse-
derived mutant Smn allele (Smn2B/ model) does not further sig-
nificantly influence SMN levels. However, as in SMA mice all
full-length SMN is derived exclusively from the SMN2 and
Smn2B/ alleles, SMN protein levels in SMA conditions highlight
the differential processing and translation of the SMN mRNAs
that are derived from these alleles in different tissues. Further
studies are now warranted to identify the cellular mechanisms
that underlie these differences, as they could provide additional
therapeutic targets for increasing SMN levels.
Although motor neurons are the primary pathological target
in SMA, other tissues have also shown to be affected, both in
patients and in animal models (11,45). This study highlights fur-
ther how substantial levels of SMN are present systemically.
When investigating defects in specific tissues in SMA, the data-
set presented in this article provides a resource for interpreting
the results in the context of overall SMN expression. Moreover,
the results are in line with a threshold model for SMN
requirement, in which CNS tissues are more sensitive to SMN
depletion than other tissues, as has been suggested previously
(46). However, our findings indicate that significant variability
can be present between tissues and mouse models, and that
considerable changes in expression occur over time, which
should be taken into account when interpreting results
obtained from individual tissues at specific time points. Future
research may be able to add further detail to these findings by
investigating the effect of SMN expression on specific cell types,
such as vulnerable and resistant populations of spinal motor
neurons (29,47,48).
In line with the large variety of systemic defects that is ob-
served in SMA, many cellular pathways have been identified to
be affected by SMN (14,15,49). Although these findings provide
important novel insights into the pathogenesis of SMA, to really
advance our understanding of SMA it is becoming increasingly
necessary to search for and identify central regulators of the
SMA disease process. Depletion of SMN in different tissues is
central to all these pathways and therefore a better understand-
ing of SMN expression over time as presented in this article can
provide a starting point for further studies. These studies will
help in answering vital questions about SMA pathogenesis that
will in turn assist in further optimization and development of
current and future therapies.
Materials and Methods
Mouse models and tissue collection
All animal work was performed in concordance with institu-
tional and Home Office regulations (PPL 60/4569). All mice were
housed at the University of Edinburgh under standard specific
pathogen-free conditions. The Taiwanese model of SMA was
originally obtained from Jackson Laboratories (strain 005058)
and maintained as described previously (22,23). Mice carrying
the Smn2B allele backcrossed onto a C57BL6 background were
originally obtained from Dr Rashmi Kothary, University of
Ottawa, Canada and bred with Smnþ/ mice obtained from
Jackson Laboratories (strain 10921). Brain, spinal cord, muscle
(M. gastrocnemius), heart, liver and kidney were quickly dissected
following humane euthanasia, immediately snap-frozen on dry
ice and stored at 80C until required for western blot analysis.
In SMA littermates from the Taiwanese model full-length SMN is
exclusively derived from the human SMN2 transgene whereas,
in the Smn2B/ model, full-length protein is derived from a
mouse allele. For consistency, we refer to SMN rather than Smn
throughout the article.
Quantitative western blotting
For western blot analysis, tissues were thawed on ice and
washed three times in ice cold PBS. Tissues were homogenized
on ice using a pestle homogenizer in radioimmunoprecipitation
assay buffer (RIPA buffer) (ThermoFisher Scientific) with prote-
ase inhibitor (Halt Protease Inhibitor Cocktail, ThermoFisher
Scientific). Sample homogenates were incubated on ice for 10
min before being centrifuged for 10 min at 4C at>13 000g.
Cleared tissue lysates were moved to a new tube and protein
concentrations were determined using the bicinchoninic acid
method (BCA method) (ThermoFisher Scientific). Protein con-
centration was normalized for all tissues at 2.5 mg/ml in MilliQ
water with 4x SDS sample buffer (ThermoFisher Scientific) con-
taining b-mercaptoethanol (Sigma-Aldrich) as a reducing agent.
For all samples and tissue types, 20 mg of protein was loaded
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onto a 4–12% Bis-Tris gradient gel (ThermoFisher Scientific), and
samples were size separated by running the gel for 10 min at
80V followed by 150V for 60 min. Proteins were subsequently
transferred to a polyvinylidene difluoride (PDVF) membrane us-
ing the iBlot2 semi-dry blotting system (ThermoFisher
Scientific). Immediately after transfer, PDVF membranes were
incubated in Revert Total Protein Stain (Li-Cor) for 5 min at
room temperature (RT), washed and blocked in Odyssey PBS
blocking buffer (Li-Cor) for 30 min at RT. All membranes were
incubated in freshly made up SMN-antibody solution (mouse-
anti-SMN, BD Bioscience 610646, 1:1000 in Odyssey blocking
buffer) and incubated overnight at 4C. After primary antibody
incubation, membranes were washed 3  10 min in 1 PBS at
RT and incubated in donkey-anti-mouse IRDye 800 (Li-Cor) sec-
ondary antibody at 1:5000 in Odyssey blocking buffer for 1 h at
RT. Membranes were washed 3  30 min in 1 PBS at RT and
dried followed by image acquisition on an Odyssey CLX laser-
based scanning system (Li-Cor).
Quantification and normalization of SMN levels across
tissues
For all analyses, TPS and anti-SMN intensity were first deter-
mined using ImageStudio (Li-Cor) and SMN levels were normal-
ized to TPS signal intensity to control for protein loading
variation. To determine the relative decrease of SMN expression
in SMA, average SMN expression for three control mice was cal-
culated and defined as 1. SMN expression in SMA mice was sub-
sequently calculated by dividing the normalized expression in
SMA samples by the average normalized expression in controls.
This returns a normalized, relative expression value for each of
the SMA samples analysed. To be able to directly compare SMN
expression across tissues and over time in control tissues, all
time points for each tissue were analysed on one western blot
membrane, in addition to an internal standard that was the
same across all membranes and tissues, and analysed concur-
rently with each of the time points. The internal standard con-
sisted of a mixture of brain protein lysates, because SMN levels
in brain are high and it is possible to obtain large quantities of
protein from brain, thereby allowing us to make a large quantity
of our internal standard that could be used consistently across
all membranes. The internal standard was loaded in triplicate
on all membranes and allowed us to correct for technical varia-
tion that could have occurred in handling and processing the in-
dividual western blotting membranes. After normalizing SMN
expression levels using TPS intensity for all samples, including
the internal standard, the average intensity value of the internal
standard was calculated and defined as 1 on each of the mem-
branes. The normalized intensity values for SMN where subse-
quently divided by the average value of the internal standard on
each of the membranes, thus allowing to compare SMN levels
across tissues. These values were used in the further statistical
analyses as described later.
Statistical analysis
To statistically determine the effects of tissue and age on SMN
expression, we modelled the expression using a mixed-effects
model, implemented in lmer (lme4 package in R) (50). The
model specified tissue type, age and the interaction between tis-
sue and age as fixed effects, and mouseID as a random effect to
account for non-independence of multiple measurements from
individual mice. As expression data for Taiwanese mice did not
meet the assumptions of homogeneity of variance and normal-
ity of the analysis, we square-root transformed the expression
data to better meet the assumptions of model residuals to the
data. To test for a significant interaction, we fitted the model a
second time, excluding the interaction and then used paramet-
ric bootstrapping (using PBmodcomp from the pbkrtest package
in R) to compare the models. To determine the differences
between individual time points and tissues, we compared SMN
expression between all combinations of age (i.e. 2 versus 5, 2
versus 8, 5 versus 8 for Taiwanese and 5 versus 10, 5 versus 15, 10
versus 15 for Smn2B/), and all combinations of tissues (brain
versus spinal cord, muscle, heart, liver, kidney, spinal cord ver-
sus muscle, heart, liver, kidney, etc.) performed separately for
each tissue (with the emmeans package in R using Tukey post
hoc analysis).
Supplementary Material
Supplementary Material is available at HMG online.
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